ID   CUL7_HUMAN              Reviewed;        1698 AA.
AC   Q14999; B4DYZ0; F5H0L1; Q5T654;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-2007, sequence version 2.
DT   28-JUN-2023, entry version 209.
DE   RecName: Full=Cullin-7;
DE            Short=CUL-7;
GN   Name=CUL7; Synonyms=KIAA0076;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-813.
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S., Seki N.,
RA   Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II. The
RT   coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ARG-813.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-813.
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION IN A COMPLEX WITH SKP1; FBXW8 AND RBX1.
RX   PubMed=12481031; DOI=10.1073/pnas.252646399;
RA   Dias D.C., Dolios G., Wang R., Pan Z.Q.;
RT   "CUL7: a DOC domain-containing cullin selectively binds Skp1.Fbx29 to form
RT   an SCF-like complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16601-16606(2002).
RN   [6]
RP   INTERACTION WITH RBX1, AND IDENTIFICATION IN A COMPLEX WITH SKP1; FBXW8;
RP   RBX1 AND GLMN.
RX   PubMed=12904573; DOI=10.1073/pnas.1733908100;
RA   Arai T., Kasper J.S., Skaar J.R., Ali S.H., Takahashi C., DeCaprio J.A.;
RT   "Targeted disruption of p185/Cul7 gene results in abnormal vascular
RT   morphogenesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:9855-9860(2003).
RN   [7]
RP   INTERACTION WITH SV40 LARGE ANTIGEN (MICROBIAL INFECTION).
RX   PubMed=16140746; DOI=10.1128/jvi.79.18.11685-11692.2005;
RA   Kasper J.S., Kuwabara H., Arai T., Ali S.H., DeCaprio J.A.;
RT   "Simian virus 40 large T antigen's association with the CUL7 SCF complex
RT   contributes to cellular transformation.";
RL   J. Virol. 79:11685-11692(2005).
RN   [8]
RP   INTERACTION WITH CUL9.
RX   PubMed=15964813; DOI=10.1128/mcb.25.13.5579-5589.2005;
RA   Skaar J.R., Arai T., DeCaprio J.A.;
RT   "Dimerization of CUL7 and PARC is not required for all CUL7 functions and
RT   mouse development.";
RL   Mol. Cell. Biol. 25:5579-5589(2005).
RN   [9]
RP   FUNCTION, INTERACTION WITH RBX1 AND TP53, AND SUBCELLULAR LOCATION.
RX   PubMed=16547496; DOI=10.1038/sj.onc.1209490;
RA   Andrews P., He Y.J., Xiong Y.;
RT   "Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes
RT   cell growth by antagonizing p53 function.";
RL   Oncogene 25:4534-4548(2006).
RN   [10]
RP   FUNCTION, INTERACTION WITH CUL9; SKP1; FBXW8; RBX1 AND TP53, AND LACK OF
RP   NEDDYLATION.
RX   PubMed=17332328; DOI=10.1158/0008-5472.can-06-3241;
RA   Skaar J.R., Florens L., Tsutsumi T., Arai T., Tron A., Swanson S.K.,
RA   Washburn M.P., DeCaprio J.A.;
RT   "PARC and CUL7 form atypical cullin RING ligase complexes.";
RL   Cancer Res. 67:2006-2014(2007).
RN   [11]
RP   INVOLVEMENT IN 3M1.
RX   PubMed=17675530; DOI=10.1136/jmg.2007.051979;
RA   Maksimova N., Hara K., Miyashia A., Nikolaeva I., Shiga A., Nogovicina A.,
RA   Sukhomyasova A., Argunov V., Shvedova A., Ikeuchi T., Nishizawa M.,
RA   Kuwano R., Onodera O.;
RT   "Clinical, molecular and histopathological features of short stature
RT   syndrome with novel CUL7 mutation in Yakuts: new population isolate in
RT   Asia.";
RL   J. Med. Genet. 44:772-778(2007).
RN   [12]
RP   FUNCTION.
RX   PubMed=18498745; DOI=10.1016/j.molcel.2008.03.009;
RA   Xu X., Sarikas A., Dias-Santagata D.C., Dolios G., Lafontant P.J.,
RA   Tsai S.C., Zhu W., Nakajima H., Nakajima H.O., Field L.J., Wang R.,
RA   Pan Z.Q.;
RT   "The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for
RT   ubiquitin-dependent degradation.";
RL   Mol. Cell 30:403-414(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-339, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   INTERACTION WITH OBSL1.
RX   PubMed=21737058; DOI=10.1016/j.ajhg.2011.05.028;
RA   Hanson D., Murray P.G., O'Sullivan J., Urquhart J., Daly S., Bhaskar S.S.,
RA   Biesecker L.G., Skae M., Smith C., Cole T., Kirk J., Chandler K.,
RA   Kingston H., Donnai D., Clayton P.E., Black G.C.;
RT   "Exome sequencing identifies CCDC8 mutations in 3-M syndrome, Suggesting
RT   that CCDC8 Contributes in a Pathway with CUL7 and OBSL1 to Control Human
RT   Growth.";
RL   Am. J. Hum. Genet. 89:148-153(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   FUNCTION, INTERACTION WITH FBXW8 AND OBSL1, AND SUBCELLULAR LOCATION.
RX   PubMed=21572988; DOI=10.1371/journal.pbio.1001060;
RA   Litterman N., Ikeuchi Y., Gallardo G., O'Connell B.C., Sowa M.E.,
RA   Gygi S.P., Harper J.W., Bonni A.;
RT   "An OBSL1-Cul7Fbxw8 ubiquitin ligase signaling mechanism regulates Golgi
RT   morphology and dendrite patterning.";
RL   PLoS Biol. 9:E1001060-E1001060(2011).
RN   [18]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=20139075; DOI=10.1074/jbc.m109.004200;
RA   Fu J., Lv X., Lin H., Wu L., Wang R., Zhou Z., Zhang B., Wang Y.L.,
RA   Tsang B.K., Zhu C., Wang H.;
RT   "Ubiquitin ligase cullin 7 induces epithelial-mesenchymal transition in
RT   human choriocarcinoma cells.";
RL   J. Biol. Chem. 285:10870-10879(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH FBXW8.
RX   PubMed=24362026; DOI=10.1074/jbc.m113.520106;
RA   Wang H., Chen Y., Lin P., Li L., Zhou G., Liu G., Logsdon C., Jin J.,
RA   Abbruzzese J.L., Tan T.H., Wang H.;
RT   "The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin
RT   ligase promotes degradation of hematopoietic progenitor kinase 1.";
RL   J. Biol. Chem. 289:4009-4017(2014).
RN   [21]
RP   FUNCTION, IDENTIFICATION IN THE 3M COMPLEX, AND SUBCELLULAR LOCATION.
RX   PubMed=24793695; DOI=10.1016/j.molcel.2014.03.047;
RA   Yan J., Yan F., Li Z., Sinnott B., Cappell K.M., Yu Y., Mo J., Duncan J.A.,
RA   Chen X., Cormier-Daire V., Whitehurst A.W., Xiong Y.;
RT   "The 3M complex maintains microtubule and genome integrity.";
RL   Mol. Cell 54:791-804(2014).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH CUL9.
RX   PubMed=24793696; DOI=10.1016/j.molcel.2014.03.046;
RA   Li Z., Pei X.H., Yan J., Yan F., Cappell K.M., Whitehurst A.W., Xiong Y.;
RT   "CUL9 mediates the functions of the 3M complex and ubiquitylates survivin
RT   to maintain genome integrity.";
RL   Mol. Cell 54:805-819(2014).
RN   [23]
RP   INTERACTION WITH HDAC4 AND HDAC5.
RX   PubMed=25752541; DOI=10.1016/j.str.2015.02.001;
RA   Nie J., Xu C., Jin J., Aka J.A., Tempel W., Nguyen V., You L., Weist R.,
RA   Min J., Pawson T., Yang X.J.;
RT   "Ankyrin repeats of ANKRA2 recognize a PxLPxL motif on the 3M syndrome
RT   protein CCDC8.";
RL   Structure 23:700-712(2015).
RN   [24]
RP   STRUCTURE BY NMR OF 360-460, AND INTERACTION WITH TP53.
RX   PubMed=17298945; DOI=10.1074/jbc.m611297200;
RA   Kaustov L., Lukin J., Lemak A., Duan S., Ho M., Doherty R., Penn L.Z.,
RA   Arrowsmith C.H.;
RT   "The conserved CPH domains of Cul7 and PARC are protein-protein interaction
RT   modules that bind the tetramerization domain of p53.";
RL   J. Biol. Chem. 282:11300-11307(2007).
RN   [25]
RP   VARIANTS 3M1 ARG-1014; GLY-1246 AND PRO-1464, AND TISSUE SPECIFICITY.
RX   PubMed=16142236; DOI=10.1038/ng1628;
RA   Huber C., Dias-Santagata D., Glaser A., O'Sullivan J., Brauner R., Wu K.,
RA   Xu X., Pearce K., Wang R., Giovannucci Uzielli M.L., Dagoneau N.,
RA   Chemaitilly W., Superti-Furga A., Dos Santos H., Megarbane A., Morin G.,
RA   Gillessen-Kaesbach G., Hennekam R.C.M., Van der Burgt I., Black G.C.M.,
RA   Clayton P.E., Read A., Le Merrer M., Scambler P.J., Munnich A., Pan Z.-Q.,
RA   Winter R., Cormier-Daire V.;
RT   "Identification of mutations in CUL7 in 3-M syndrome.";
RL   Nat. Genet. 37:1119-1124(2005).
RN   [26]
RP   VARIANT 3M1 PRO-1588.
RX   PubMed=23018678; DOI=10.1530/jme-12-0034;
RA   Hanson D., Murray P.G., Coulson T., Sud A., Omokanye A., Stratta E.,
RA   Sakhinia F., Bonshek C., Wilson L.C., Wakeling E., Temtamy S.A., Aglan M.,
RA   Rosser E.M., Mansour S., Carcavilla A., Nampoothiri S., Khan W.I.,
RA   Banerjee I., Chandler K.E., Black G.C., Clayton P.E.;
RT   "Mutations in CUL7, OBSL1 and CCDC8 in 3-M syndrome lead to disordered
RT   growth factor signalling.";
RL   J. Mol. Endocrinol. 49:267-275(2012).
CC   -!- FUNCTION: Core component of the 3M and Cul7-RING(FBXW8) complexes,
CC       which mediates the ubiquitination of target proteins. Core component of
CC       the 3M complex, a complex required to regulate microtubule dynamics and
CC       genome integrity. It is unclear how the 3M complex regulates
CC       microtubules, it could act by controlling the level of a microtubule
CC       stabilizer (PubMed:24793695). Interaction with CUL9 is required to
CC       inhibit CUL9 activity and ubiquitination of BIRC5 (PubMed:24793696).
CC       Core component of a Cul7-RING ubiquitin-protein ligase with FBXW8,
CC       which mediates ubiquitination and consequent degradation of target
CC       proteins such as GORASP1, IRS1 and MAP4K1/HPK1 (PubMed:21572988,
CC       PubMed:24362026). Ubiquitination of GORASP1 regulates Golgi
CC       morphogenesis and dendrite patterning in brain (PubMed:21572988).
CC       Mediates ubiquitination and degradation of IRS1 in a mTOR-dependent
CC       manner: the Cul7-RING(FBXW8) complex recognizes and binds IRS1
CC       previously phosphorylated by S6 kinase (RPS6KB1 or RPS6KB2)
CC       (PubMed:18498745). The Cul7-RING(FBXW8) complex also mediates
CC       ubiquitination of MAP4K1/HPK1: recognizes and binds autophosphorylated
CC       MAP4K1/HPK1, leading to its degradation, thereby affecting cell
CC       proliferation and differentiation (PubMed:24362026). Acts as a
CC       regulator in trophoblast cell epithelial-mesenchymal transition and
CC       placental development (PubMed:20139075). Does not promote
CC       polyubiquitination and proteasomal degradation of p53/TP53
CC       (PubMed:16547496, PubMed:17332328). While the Cul7-RING(FBXW8) and the
CC       3M complexes are associated and involved in common processes, CUL7 and
CC       the Cul7-RING(FBXW8) complex may be have additional functions.
CC       {ECO:0000269|PubMed:16547496, ECO:0000269|PubMed:17332328,
CC       ECO:0000269|PubMed:18498745, ECO:0000269|PubMed:20139075,
CC       ECO:0000269|PubMed:21572988, ECO:0000269|PubMed:24362026,
CC       ECO:0000269|PubMed:24793695, ECO:0000269|PubMed:24793696}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Component of the 3M complex, composed of core components CUL7,
CC       CCDC8 and OBSL1. Part of a Cul7-RING complex consisting of CUL7, RBX1,
CC       SKP1 and FBXW8. Interacts with a complex of SKP1 and FBXW8, but not
CC       with SKP1 alone. Interacts with CUL9; leading to inhibit CUL9 activity.
CC       Interacts with FBXW8; interaction is mutually exclusive of binding to
CC       CUL9 or p53/TP53. Interacts with p53/TP53; the interaction
CC       preferentially involves tetrameric and dimeric p53/TP53. The CUL7-CUL9
CC       heterodimer seems to interact specifically with p53/TP53. Interacts
CC       with CUL1; the interactions seems to be mediated by FBXW8. Interacts
CC       with OBSL1. Interacts (as part of the 3M complex) with HDAC4 and HDAC5;
CC       it is negatively regulated by ANKRA2. {ECO:0000269|PubMed:12481031,
CC       ECO:0000269|PubMed:12904573, ECO:0000269|PubMed:15964813,
CC       ECO:0000269|PubMed:16547496, ECO:0000269|PubMed:17298945,
CC       ECO:0000269|PubMed:17332328, ECO:0000269|PubMed:21572988,
CC       ECO:0000269|PubMed:21737058, ECO:0000269|PubMed:24362026,
CC       ECO:0000269|PubMed:24793695, ECO:0000269|PubMed:24793696,
CC       ECO:0000269|PubMed:25752541}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SV40 Large T antigen;
CC       this interaction seems to inhibit CUL7. {ECO:0000269|PubMed:16140746}.
CC   -!- INTERACTION:
CC       Q14999; O75147-2: OBSL1; NbExp=4; IntAct=EBI-308606, EBI-15927144;
CC       Q14999; P04637: TP53; NbExp=8; IntAct=EBI-308606, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome. Cytoplasm, perinuclear region. Golgi
CC       apparatus. Note=Colocalizes with FBXW8 at the Golgi apparatus in
CC       neurons; localization to Golgi is mediated by OBSL1. During mitosis,
CC       localizes to the mitotic apparatus (PubMed:24793695). CCDC8 is required
CC       for centrosomal location (PubMed:24793695).
CC       {ECO:0000269|PubMed:24793695}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14999-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14999-2; Sequence=VSP_046105, VSP_046106;
CC   -!- TISSUE SPECIFICITY: Highly expressed in fetal kidney and adult skeletal
CC       muscle. Also abundant in fetal brain, as well as in adult pancreas,
CC       kidney, placenta and heart. Detected in trophoblasts, lymphoblasts,
CC       osteoblasts, chondrocytes and skin fibroblasts.
CC       {ECO:0000269|PubMed:16142236}.
CC   -!- DEVELOPMENTAL STAGE: Highly expressed in invasive placental villi
CC       during first trimester. {ECO:0000269|PubMed:20139075}.
CC   -!- PTM: According to a report, may not be neddylated despite the conserved
CC       consensus site for neddylation at Lys-1576.
CC       {ECO:0000269|PubMed:17332328}.
CC   -!- DISEASE: 3M syndrome 1 (3M1) [MIM:273750]: An autosomal recessive
CC       disorder characterized by severe pre- and postnatal growth retardation,
CC       facial dysmorphism, large head circumference, and normal intelligence
CC       and endocrine function. Skeletal changes include long slender tubular
CC       bones and tall vertebral bodies. {ECO:0000269|PubMed:16142236,
CC       ECO:0000269|PubMed:17675530, ECO:0000269|PubMed:23018678}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the cullin family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00330}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA07551.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D38548; BAA07551.2; ALT_INIT; mRNA.
DR   EMBL; AK302668; BAG63902.1; -; mRNA.
DR   EMBL; AL355385; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL136304; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC033647; AAH33647.1; -; mRNA.
DR   CCDS; CCDS4881.1; -. [Q14999-1]
DR   RefSeq; NP_001161842.1; NM_001168370.1.
DR   RefSeq; NP_055595.2; NM_014780.4. [Q14999-1]
DR   PDB; 2JNG; NMR; -; A=360-460.
DR   PDB; 7Z8B; EM; 2.80 A; C=1-1698.
DR   PDBsum; 2JNG; -.
DR   PDBsum; 7Z8B; -.
DR   AlphaFoldDB; Q14999; -.
DR   BMRB; Q14999; -.
DR   SMR; Q14999; -.
DR   BioGRID; 115159; 851.
DR   ComplexPortal; CPX-2838; 3M complex.
DR   CORUM; Q14999; -.
DR   DIP; DIP-31618N; -.
DR   DIP; DIP-60187N; -.
DR   IntAct; Q14999; 40.
DR   MINT; Q14999; -.
DR   STRING; 9606.ENSP00000438788; -.
DR   GlyGen; Q14999; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q14999; -.
DR   PhosphoSitePlus; Q14999; -.
DR   BioMuta; CUL7; -.
DR   DMDM; 160370003; -.
DR   EPD; Q14999; -.
DR   jPOST; Q14999; -.
DR   MassIVE; Q14999; -.
DR   MaxQB; Q14999; -.
DR   PaxDb; Q14999; -.
DR   PeptideAtlas; Q14999; -.
DR   ProteomicsDB; 25372; -.
DR   ProteomicsDB; 60290; -. [Q14999-1]
DR   Antibodypedia; 4223; 218 antibodies from 37 providers.
DR   DNASU; 9820; -.
DR   Ensembl; ENST00000265348.9; ENSP00000265348.4; ENSG00000044090.13. [Q14999-1]
DR   Ensembl; ENST00000690231.1; ENSP00000508461.1; ENSG00000044090.13. [Q14999-1]
DR   GeneID; 9820; -.
DR   KEGG; hsa:9820; -.
DR   MANE-Select; ENST00000265348.9; ENSP00000265348.4; NM_014780.5; NP_055595.2.
DR   UCSC; uc003otq.4; human. [Q14999-1]
DR   AGR; HGNC:21024; -.
DR   CTD; 9820; -.
DR   DisGeNET; 9820; -.
DR   GeneCards; CUL7; -.
DR   GeneReviews; CUL7; -.
DR   HGNC; HGNC:21024; CUL7.
DR   HPA; ENSG00000044090; Low tissue specificity.
DR   MalaCards; CUL7; -.
DR   MIM; 273750; phenotype.
DR   MIM; 609577; gene.
DR   neXtProt; NX_Q14999; -.
DR   OpenTargets; ENSG00000044090; -.
DR   Orphanet; 2616; 3M syndrome.
DR   PharmGKB; PA134897835; -.
DR   VEuPathDB; HostDB:ENSG00000044090; -.
DR   eggNOG; ENOG502RDJD; Eukaryota.
DR   GeneTree; ENSGT00940000153954; -.
DR   HOGENOM; CLU_001067_1_0_1; -.
DR   InParanoid; Q14999; -.
DR   OMA; RCWPVAS; -.
DR   OrthoDB; 4161627at2759; -.
DR   PhylomeDB; Q14999; -.
DR   TreeFam; TF101154; -.
DR   PathwayCommons; Q14999; -.
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q14999; -.
DR   SIGNOR; Q14999; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 9820; 83 hits in 1211 CRISPR screens.
DR   ChiTaRS; CUL7; human.
DR   EvolutionaryTrace; Q14999; -.
DR   GeneWiki; CUL7; -.
DR   GenomeRNAi; 9820; -.
DR   Pharos; Q14999; Tbio.
DR   PRO; PR:Q14999; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q14999; protein.
DR   Bgee; ENSG00000044090; Expressed in stromal cell of endometrium and 193 other tissues.
DR   ExpressionAtlas; Q14999; baseline and differential.
DR   Genevisible; Q14999; HS.
DR   GO; GO:1990393; C:3M complex; IDA:UniProtKB.
DR   GO; GO:0005680; C:anaphase-promoting complex; NAS:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0031467; C:Cul7-RING ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:InterPro.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0007030; P:Golgi organization; ISS:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB.
DR   GO; GO:0001890; P:placenta development; IDA:UniProtKB.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; IGI:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; NAS:UniProtKB.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; IMP:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   CDD; cd08665; APC10-CUL7; 1.
DR   Gene3D; 2.30.30.30; -; 1.
DR   Gene3D; 1.20.1310.10; Cullin Repeats; 1.
DR   Gene3D; 2.60.120.260; Galactose-binding domain-like; 1.
DR   Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1.
DR   InterPro; IPR004939; APC_su10/DOC_dom.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR021097; CPH_domain.
DR   InterPro; IPR045093; Cullin.
DR   InterPro; IPR016158; Cullin_homology.
DR   InterPro; IPR036317; Cullin_homology_sf.
DR   InterPro; IPR001373; Cullin_N.
DR   InterPro; IPR019559; Cullin_neddylation_domain.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR014722; Rib_L2_dom2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   PANTHER; PTHR22771; CULLIN AND GALACTOSE-BINDING DOMAIN-CONTAINING; 1.
DR   PANTHER; PTHR22771:SF3; CULLIN-7; 1.
DR   Pfam; PF03256; ANAPC10; 1.
DR   Pfam; PF11515; Cul7; 1.
DR   Pfam; PF00888; Cullin; 1.
DR   SMART; SM01337; APC10; 1.
DR   SMART; SM00884; Cullin_Nedd8; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   SUPFAM; SSF75632; Cullin homology domain; 1.
DR   SUPFAM; SSF49785; Galactose-binding domain-like; 1.
DR   SUPFAM; SSF63748; Tudor/PWWP/MBT; 1.
DR   PROSITE; PS50069; CULLIN_2; 1.
DR   PROSITE; PS51284; DOC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Cytoskeleton;
KW   Disease variant; Dwarfism; Golgi apparatus; Host-virus interaction;
KW   Isopeptide bond; Phosphoprotein; Reference proteome; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   CHAIN           1..1698
FT                   /note="Cullin-7"
FT                   /id="PRO_0000119802"
FT   DOMAIN          814..993
FT                   /note="DOC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00614"
FT   REGION          315..357
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          360..460
FT                   /note="Interaction with TP53"
FT   REGION          601..623
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1345..1370
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1345..1362
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         339
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   CROSSLNK        1576
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in NEDD8)"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1
FT                   /note="M -> MSRGFWLAEPLAGTGPHPAPVAADSRGCSSVPRRHAPSRLSVSTPSR
FT                   GPGARM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046105"
FT   VAR_SEQ         194
FT                   /note="G -> GEGQCGEEGKAGEGLGRLRDSQDTVAGASDLIR (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046106"
FT   VARIANT         616
FT                   /note="S -> G (in dbSNP:rs7774330)"
FT                   /id="VAR_048841"
FT   VARIANT         813
FT                   /note="Q -> R (in dbSNP:rs9381231)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:7584044"
FT                   /id="VAR_026121"
FT   VARIANT         852
FT                   /note="R -> Q (in dbSNP:rs34574340)"
FT                   /id="VAR_048842"
FT   VARIANT         1014
FT                   /note="L -> R (in 3M1; unknown pathological significance;
FT                   dbSNP:rs61752334)"
FT                   /evidence="ECO:0000269|PubMed:16142236"
FT                   /id="VAR_026122"
FT   VARIANT         1246
FT                   /note="Q -> G (in 3M1; requires 2 nucleotide
FT                   substitutions)"
FT                   /evidence="ECO:0000269|PubMed:16142236"
FT                   /id="VAR_026123"
FT   VARIANT         1246
FT                   /note="Q -> H (in dbSNP:rs36071170)"
FT                   /id="VAR_048843"
FT   VARIANT         1464
FT                   /note="H -> P (in 3M1; impairs the ability to interact with
FT                   RBX1, thus hampers the assembly of polyubiquitin chains;
FT                   dbSNP:rs121918229)"
FT                   /evidence="ECO:0000269|PubMed:16142236"
FT                   /id="VAR_026124"
FT   VARIANT         1588
FT                   /note="L -> P (in 3M1; dbSNP:rs759300846)"
FT                   /evidence="ECO:0000269|PubMed:23018678"
FT                   /id="VAR_071120"
FT   STRAND          12..15
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          18..30
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          34..45
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          63..69
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           71..77
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           79..81
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   TURN            82..84
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           116..119
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           142..148
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          150..152
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           153..157
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   TURN            158..161
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           162..170
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           176..186
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           198..204
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   TURN            207..211
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           216..228
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           247..268
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           288..310
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           360..362
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   STRAND          363..366
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   HELIX           367..376
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   STRAND          382..385
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   STRAND          397..403
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   STRAND          407..414
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   TURN            415..418
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   STRAND          419..424
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   HELIX           425..427
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   STRAND          428..430
FT                   /evidence="ECO:0007829|PDB:2JNG"
FT   HELIX           467..469
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           491..501
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           506..519
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           526..529
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           537..546
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           553..561
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   TURN            563..567
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           620..625
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           633..640
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           652..661
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           664..671
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   TURN            680..682
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           683..693
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          696..698
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           699..701
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           704..706
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           711..714
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           723..738
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           741..749
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           751..759
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   TURN            760..762
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          766..768
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           769..810
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           820..828
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          841..848
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           850..856
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          857..859
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          874..880
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          887..892
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          897..912
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   TURN            913..915
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          918..924
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          930..935
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          943..952
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           953..955
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          963..967
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           977..1002
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1004..1009
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1010..1028
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1029..1031
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1032..1055
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1059..1061
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1064..1074
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1087..1100
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1128..1131
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1139..1161
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1162..1164
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1168..1187
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1191..1205
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1210..1229
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1239..1252
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1253..1255
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1258..1260
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1261..1276
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1284..1292
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1293..1295
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1300..1324
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1388..1394
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1419..1432
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1448..1458
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1464..1466
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1467..1477
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1484..1491
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1498..1502
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1504..1506
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1507..1509
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1524..1526
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1529..1531
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1555..1576
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   TURN            1577..1581
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1585..1597
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1600..1602
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1604..1609
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   HELIX           1618..1631
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1633..1636
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1638..1640
FT                   /evidence="ECO:0007829|PDB:7Z8B"
FT   STRAND          1643..1646
FT                   /evidence="ECO:0007829|PDB:7Z8B"
SQ   SEQUENCE   1698 AA;  191161 MW;  EC9EED17E98FC9A1 CRC64;
     MVGELRYREF RVPLGPGLHA YPDELIRQRV GHDGHPEYQI RWLILRRGDE GDGGSGQVDC
     KAEHILLWMS KDEIYANCHK MLGEDGQVIG PSQESAGEVG ALDKSVLEEM ETDVKSLIQR
     ALRQLEECVG TIPPAPLLHT VHVLSAYASI EPLTGVFKDP RVLDLLMHML SSPDYQIRWS
     AGRMIQALSS HDAGTRTQIL LSLSQQEAIE KHLDFDSRCA LLALFAQATL SEHPMSFEGI
     QLPQVPGRVL FSLVKRYLHV TSLLDQLNDS AAEPGAQNTS APEELSGERG QLELEFSMAM
     GTLISELVQA MRWDQASDRP RSSARSPGSI FQPQLADVSP GLPAAQAQPS FRRSRRFRPR
     SEFASGNTYA LYVRDTLQPG MRVRMLDDYE EISAGDEGEF RQSNNGVPPV QVFWESTGRT
     YWVHWHMLEI LGFEEDIEDM VEADEYQGAV ASRVLGRALP AWRWRPMTEL YAVPYVLPED
     EDTEECEHLT LAEWWELLFF IKKLDGPDHQ EVLQILQENL DGEILDDEIL AELAVPIELA
     QDLLLTLPQR LNDSALRDLI NCHVYKKYGP EALAGNQAYP SLLEAQEDVL LLDAQAQAKD
     SEDAAKVEAK EPPSQSPNTP LQRLVEGYGP AGKILLDLEQ ALSSEGTQEN KVKPLLLQLQ
     RQPQPFLALM QSLDTPETNR TLHLTVLRIL KQLVDFPEAL LLPWHEAVDA CMACLRSPNT
     DREVLQELIF FLHRLTSVSR DYAVVLNQLG ARDAISKALE KHLGKLELAQ ELRDMVFKCE
     KHAHLYRKLI TNILGGCIQM VLGQIEDHRR THQPINIPFF DVFLRYLCQG SSVEVKEDKC
     WEKVEVSSNP HRASKLTDHN PKTYWESNGS AGSHYITLHM RRGILIRQLT LLVASEDSSY
     MPARVVVCGG DSTSSLHTEL NSVNVMPSAS RVILLENLTR FWPIIQIRIK RCQQGGIDTR
     IRGLEILGPK PTFWPVFREQ LCRHTRLFYM VRAQAWSQDM AEDRRSLLHL SSRLNGALRQ
     EQNFADRFLP DDEAAQALGK TCWEALVSPV VQNITSPDED GISPLGWLLD QYLECQEAVF
     NPQSRGPAFF SRVRRLTHLL VHVEPCEAPP PVVATPRPKG RNRSHDWSSL ATRGLPSSIM
     RNLTRCWRAV VEKQVNNFLT SSWRDDDFVP RYCEHFNILQ NSSSELFGPR AAFLLALQNG
     CAGALLKLPF LKAAHVSEQF ARHIDQQIQG SRIGGAQEME RLAQLQQCLQ AVLIFSGLEI
     ATTFEHYYQH YMADRLLGVV SSWLEGAVLE QIGPCFPNRL PQQMLQSLST SKELQRQFHV
     YQLQQLDQEL LKLEDTEKKI QVGLGASGKE HKSEKEEEAG AAAVVDVAEG EEEEEENEDL
     YYEGAMPEVS VLVLSRHSWP VASICHTLNP RTCLPSYLRG TLNRYSNFYN KSQSHPALER
     GSQRRLQWTW LGWAELQFGN QTLHVSTVQM WLLLYLNDLK AVSVESLLAF SGLSADMLNQ
     AIGPLTSSRG PLDLHEQKDI PGGVLKIRDG SKEPRSRWDI VRLIPPQTYL QAEGEDGQNL
     EKRRNLLNCL IVRILKAHGD EGLHIDQLVC LVLEAWQKGP CPPRGLVSSL GKGSACSSTD
     VLSCILHLLG KGTLRRHDDR PQVLSYAVPV TVMEPHTESL NPGSSGPNPP LTFHTLQIRS
     RGVPYASCTA TQSFSTFR
//
